Disclosed is the use of a glitazone in the preparation of a medicament for the treatment of inflammatory respiratory disease by pulmonary administration by inhalation, wherein said disease is selected from mild asthma, moderate asthma, severe asthma, steroid resistant asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary edema, pulmonary embolism, pneumonia, pulmonary sarcoidosis, silicosis, pulmonary fibrosis, respiratory failure, acute respiratory distres...

KINASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY The present invention relates to a method of treating an individual or animal with diabetes and/or obesity. The method includes administering to the individual or animal a therapeutically effective amount of a protein tyrosine kinase inhibitor. Preferably, the preventative and therapeutic methods of the present invention involve administering - to a mammal in need thereof - a therapeutically effective amount of an inhibitor of a c-Src f...

A pharmaceutical composition comprising rosiglitazone or a pharmaceutically acceptable salt thereof wherein said rosiglitazone has a median particle size diameter of about 5 microns to about 20 microns.

The present invention relates to a pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings, wherein the pharmaceutical composition contains (R)-7-[3-amino-4-(2, 4, 5-trifluo-phenyl)-butyryl]-3-trifluomethyl-5, 6, 7, 8-tetrahydro-imidazo[1, 5-a]pyrazine-1-carboxylic acid methyl ester or its pharmaceutically acceptable salts and rosiglitazone or pioglitazone or their pharmaceutically acceptable salts, preparation method thereof and a method of treating typ...